Dublin, June 18, 2019 (GLOBE NEWSWIRE) -- The "Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.
The Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 - 2030 report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs.
Amongst other elements, the report includes:
- A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
- Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
- A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody-drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
- A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
- A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
- A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug/therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
- An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
- An analysis of the recent trends within the biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
- A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical/clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
- An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
- A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
- A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
- One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as the growth of the overall biopharmaceutical market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), [B] types of expression systems (mammalian, microbial and others), [C] size of the company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world (Australia)). To account for the uncertainties associated with the manufacturing of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
Key Topics Covered:
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Context and Background
3.2. An Overview of Biopharmaceuticals
3.3. Biopharmaceutical Manufacturing
3.3.1. Types of Expression Systems
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Yeast Expression Systems
3.3.1.3. Fungal Expression Systems
3.3.1.4. Insect Expression Systems
3.3.1.5. Plant Expression Systems
3.3.1.6. Mammalian Expression Systems
3.3.2. Processing Steps
3.3.2.1. Upstream Processing
3.3.2.2. Downstream Processing
3.4. An Overview of Contract Manufacturing
3.5. Need for Outsourcing in the Biopharmaceutical Industry
3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry
3.7. Basic Guidelines for Selecting a CMO Partner
3.8. Advantages of Outsourcing Manufacturing Services
3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
3.10. Future Perspectives
4. Competitive Landscape
4.1. Chapter Overview
4.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Size of Employee Base
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facilities
4.2.5. Analysis by Type of Biologics Manufactured
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Expression Systems
4.2.8. Analysis by Type of Bioreactor and Mode of Operation
4.2.9. Analysis by Biomanufacturing Capacity
4.2.10. Analysis by Packaging Form
5. Biopharmaceutical Contract Manufacturing In North America
5.1. Chapter Overview
5.2. Biopharmaceutical Outsourcing in the US: Regulatory Scenario
5.3. Leading Biopharma CMOs in North America
5.3.1. AMRI (OsoBio)
5.3.2. Baxter BioPharma Solutions
5.3.3. Catalent Biologics (Catalent Pharma Solutions)
5.3.4. Cytovance Biologics
5.3.5. Patheon
5.3.6. Piramal Pharma Solutions
6. Biopharmaceutical Contract Manufacturing In Europe
6.1. Chapter Overview
6.2. Biopharmaceutical Outsourcing in Europe: Regulatory Scenario
6.3. Leading Biopharmaceutical CMOs in Europe
6.3.1. 3P Biopharmaceuticals
6.3.2. Boehringer Ingelheim BioXcellence
6.3.3. Celonic
6.3.4. FUJIFILM Diosynth Biotechnologies
6.3.5. LFB Group
6.3.6. Lonza
6.3.7. Menarini Biotech
6.3.8. Novasep
6.3.9. Rentschler BioPharma
7. Biopharmaceutical Contract Manufacturing In Asia Pacific And The Rest Of The World
7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturing in China
7.2.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
7.3. Biopharmaceutical CMOs in China
7.3.1. AutekBio
7.3.2. WuXi AppTec (WuXi Biologics)
7.4. Biopharmaceutical Contract Manufacturing in India
7.4.1. Biopharmaceutical Outsourcing in India: Regulatory Scenario
7.5. Biopharmaceutical CMOs in India
7.5.1. Intas Pharmaceuticals
7.5.2. Kemwell Biopharma
7.5.4. Shasun Pharmaceuticals
7.5.5. Syngene
7.6. Biopharmaceutical Contract Manufacturing in Japan
7.6.1. Biopharmaceutical Outsourcing in Japan: Regulatory Scenario
7.7. Biopharmaceutical CMOs in Japan
7.7.1. Asahi Glass
7.8. Biopharmaceutical Contract Manufacturing in South Korea
7.8.1. Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario
7.9. Biopharmaceutical CMOs in South Korea
7.9.1. DM Bio
7.9.2. Samsung BioLogics
7.10. Biopharmaceutical Contract Manufacturing in Australia
7.10.1. Biopharmaceutical Outsourcing in Australia: Regulatory Scenario
7.11. Biopharmaceutical CMOs in Australia
7.11.1. Cell Therapies
7.11.2. Luina Bio
8. Niche Biopharmaceutical Sectors
8.1. Chapter Overview
8.2. Antibody Drug Conjugates
8.2.1. Introduction
8.2.1.1. Manufacturing Process
8.2.1.2. Key Technologies and Technology Providers
8.2.2. Pipeline Analysis
8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules
8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules
8.2.2.3. ADC Manufacturing: Key Challenges
8.3. Bispecific Antibodies
8.3.1. Introduction
8.3.1.1.The Bispecific Advantage
8.3.2. Pipeline Analysis
8.3.3. Bispecific Antibody Technology Providers
8.3.4. Contract Manufacturing Scenario
8.4. Cell Therapies
8.4.1. Introduction
8.4.2. Current Market Landscape
8.4.3. Cell Therapy Manufacturing
8.4.4. Cell Therapy Manufacturing Models
8.4.4.1. Centralized Manufacturing Model
8.4.4.2. Decentralized Manufacturing Model
8.4.5. Cell Therapy Manufacturing: Key Challenges and Growth Drivers
8.4.6. Important Factors for Cell Therapy Manufacturing
8.4.7. Contract Manufacturing Scenario
8.4.7.1. Contract Manufacturing Market Landscape
8.4.7.2. Analysis by Type of Cells Manufactured
8.4.7.3. Analysis by Scale of Operation
8.5. Gene Therapy
8.5.1. Introduction
8.5.2. Gene Therapy: Pipeline Analysis
8.5.2.1. Analysis by Phase of Development
8.5.2.2. Analysis by Type of Vector
8.5.2.3. Analysis by Therapeutic Area
8.5.3. Contract Manufacturing Market Landscape
8.5.3.1. Analysis by Location
8.5.3.2. Analysis by Type of Viral Vector
8.5.3.3. Analysis by Scale of Production
8.6. Plasmid DNA
8.6.1. Introduction
8.6.2. Contract Manufacturing Market Landscape
8.6.3. Analysis by Location of Manufacturing Facility
8.6.4. Analysis by Scale of Production
9. Case Study: Outsourcing Of Biosimilars
9.1. Chapter Overview
9.2. Biosimilars: An Introduction
9.3. Biosimilars: Development Stages
9.4. Regulatory Requirements for Licensing Biosimilars
9.5. Need for Outsourcing Biosimilar Development and Manufacturing
9.6. Impact of Biosimilars on the Global Contract Manufacturing Market
9.6.1. Region-wise Distribution of Biosimilar Development / Manufacturing Activity
9.7. Challenges Associated with Outsourcing Biosimilars
10. Case Study: Comparison Of Small Molecule Andlarge Molecule Drugs/Therapies
10.1. Chapter Overview
10.2. Small Molecule and Large Molecule Drugs / Therapies
10.2.1. Comparison of General Characteristics
10.2.2. Comparison of Key Specifications
10.2.3. Comparison of Manufacturing Processes
10.2.4. Comparison of Key Manufacturing Challenges
11. Case Study On In-House Manufacturing
11.1. Chapter Overview
11.2. In-House Manufacturing
11.2.1. Benefits Associated with In-House Manufacturing
11.2.2. Risks Associated with In-House Manufacturing
11.3. Outsourcing in the Biomanufacturing Industry
11.3.1. Types of Outsourcing Partners
11.4. Manufacturing Approaches Used for Approved Biologics (2016-2018)
11.4.1. Approved Biologics: Analysis by Size of Developer and Type of Manufacturing Approach
11.4.2. Approved Biologics: Analysis by Size of Developer and Type of Biologic
11.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing
12. Collaborations
12.1. Chapter Overview
12.2. Partnership Models
12.3. Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.2.1. Year-Wise Trend of Product-based Agreements
12.3.2.2. Year-Wise Trend of Process-based Agreements
12.3.2.3. Year-Wise Trend of Licensing Agreements
12.3.2.4. Year-Wise Trend of Co-service Agreements / Ventures
12.3.2.5. Year-Wise Trend of R&D Agreements
12.3.2.6. Year-Wise Trend of Out-sourcing Services Agreements
12.3.3. Analysis by Focus Area
12.3.4. Analysis by Type of Biologic
12.3.4.1. Analysis by Type of Biologic and Type of Partnership Model
12.3.4.2. Analysis of Cell Therapy-related Deals by Year and Type of Partnership Model
12.3.4.3. Analysis of Monoclonal Antibody-related Deals Year and Type of Partnership Model
12.3.4.4. Analysis of Vaccine-related Deals by Year and Type of Partnership Model
12.3.4.5. Analysis of Protein-related Deals by Year and Type of Partnership Model
12.3.4.6. Analysis of Antibody Drug Conjugate-related Deals by Year and Type of Partnership Model
12.3.4.7. Analysis of Vector-related Deals by Year and Type of Partnership Model
12.3.4.8. Analysis of Gene Therapy-related Deals by Year and Type of Partnership Model
12.3.4.9. Analysis of Biosimilar-related Deals by Year and Type of Partnership Model
12.3.4.10. Analysis of Other Biologic-related Deals by Type of Partnership Model
12.3.4.11. Analysis by Type of Biologic and Geography
12.3.5. Analysis by Therapeutic Area
12.3.6. Analysis of Most Active Players by Number of Partnerships
12.3.7. Regional Analysis
12.3.7.1. Intercontinental and Intracontinental Agreements
12.4. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
12.4.1. Cumulative Year-wise Trend
12.4.2. Analysis by Type of Acquisition
12.4.3. Regional Analysis
12.4.3.1. Continent-wise Distribution
12.4.3.2. Country-wise Distribution
12.4.3.3. Intercontinental and Intracontinental Deals
12.4.4. Analysis of Most Active Acquirers by Number of Acquisitions
12.4.5. Analysis by Key Value Drivers
12.4.5.1. Analysis by Key Value Drivers and Year of Acquisition
12.4.6. Analysis by Type of Biologic
12.5.6.1. Analysis by Type of Biologic and Key Value Drivers
12.4.7 Key Acquisitions: Deal Multiples
13. Recent Developments
13.1. Chapter Overview
13.2. Biopharmaceutical Contract Manufacturing Market: Facility Expansions
13.2.1. Cumulative Year-wise Distribution
13.2.2. Analysis by Purpose of Facility Expansion
13.2.3. Analysis by Type of Biologic
13.2.4. Analysis by Location of Facility
13.2.5. Regional Analysis
13.2.6. Analysis by Region and Purpose
13.3. Biopharmaceutical Contract Manufacturing Market: Funding Instances
13.4. Technological Advancements
13.4.1. Single Use Technology
13.4.2. Process Analytical Technology
13.4.3. Continuous Processing
13.4.4. Quality by Design in Bio-processing
14. Capacity Analysis
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Biopharmaceutical Contract Manufacturers: Global Production Capacity
14.3.1. Analysis by Region
14.3.2. Analysis by Expression Systems
14.3.3. Analysis by Scale of Operation
14.4. ADC Contract Manufacturers: Global Production Capacity
14.5. Cell Therapy Manufacturers: Production Capacity
14.6. Vector Manufacturers: Production Capacity
14.7. Concluding Remarks
15. Demand Analysis
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Biopharmaceutical Contract Manufacturing Market: Overall Annual Demand
15.3.1. Analysis by Therapeutic Area
15.4. ADCs: Overall Annual Demand
15.4.1. ADCs: Demand and Supply Analysis
16. Market Forecast
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030
16.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030
16.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030
16.4. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used
16.5. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
16.6. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers
16.7. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography
17. SWOT Analysis
17.1 Chapter Overview
17.2. Strengths
17.3. Weaknesses
17.4. Opportunities
17.5. Threats
17.6. Comparison of Swot Factors
17.7. Concluding Remarks
18. Future Of The Biopharmaceutical CMO Market
18.1. Chapter Overview
18.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
18.3. Shift from One-time Contracts to Strategic Partnerships
18.4. Integration / Adoption of New and Innovative Technologies
18.4.1. Single use Bioreactors
18.4.2. Novel Bioprocess Techniques
18.4.3. Bioprocess Automation
18.5. Focus on Niche Therapeutic Areas
18.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
18.7. Capability and Expertise Expansions by CMOs to become One Stop Shops
18.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
18.9. Increase in Financial Inflow and Outsourcing Budgets
18.10. The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies
18.11. Challenges Faced by both Sponsors and Service Providers
18.11.1. Concerns related to Single Use Systems
18.11.2. Issues Related to Capacity Fluctuations
18.12. Concluding Remarks
19. Survey Analysis
19.1. Chapter Overview
19.1.1. Overview of Respondents
19.1.2. Designation of Respondents
19.2. Biologics Manufacturing Expertise
19.3. Scale of Manufacturing
19.4. Location of Production Facilities
19.5. Types of Expression Systems Used
19.6. Types of Bioreactors
19.7. Modes of Operation of Bioreactors
20. Interview Transcripts
20.1. Chapter Overview
20.2. Astrid Brammer, Senior Manager Business Development, Richter-Helm
20.3. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
20.4. Christian Bailly, Director of CDMO, Pierre Fabre
20.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
20.6. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
20.7. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
20.8. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
20.9. Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
20.10. Kevin Daley, Director Pharmaceuticals, Novasep
20.11. Mark Wright, Site Head, Grangemouth, Piramal Healthcare
20.12. Nicolas Grandchamp, R&D Leader, GEG Tech
20.13. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
20.14. Sebastian Schuck, Head of Business Development, Wacker Biotech
20.15. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
20.16. Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
20.17. Tim Oldham, Chief Executive Officer, Cell Therapies
21. Appendix 1: List Of Non-Industry Players
22. Appendix 2: Tabulated Data
23. Appendix 3: List Of Companies And Organizations
For more information about this report visit https://www.researchandmarkets.com/r/d9oa6h
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.